What is the 13F Pro Quality Score for CLPT?

13F Pro ranks ClearPoint Neuro, Inc. (CLPT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CLPT's current score at https://13fpro.ai/company/CLPT (free sign-up required for the full ranking).

Which hedge funds own the most CLPT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CLPT include BlackRock,, MAK CAPITAL ONE, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CLPT as soon as new 13F filings post.

Where does 13F Pro source CLPT data?

All ClearPoint Neuro, Inc. fundamentals and ownership data come directly from SEC EDGAR. ClearPoint Neuro, Inc. files with the SEC under CIK 1285550. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CLPT in?

ClearPoint Neuro, Inc. (CLPT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CLPT research updated on 13F Pro?

CLPT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ClearPoint Neuro, Inc.(CLPT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1285550 CLPT stock profile & AI dashboard →

13F Pro Quality Score

26.1/100

Rank #2,639 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

84.0/100

Profitability

7.9/100

Balance Sheet

4.0/100

Earnings Quality

15.3/100

Free Cash Flow

7.6/100

Institutional Flow

56.6/100

Revenue Scale

7.6/100

Dilution Risk

8.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CLPT Scores 26/100

exact factor attribution · 2026-09-11

CLPT's composite is driven by revenue growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.8 pts

84th pct

Institutional flow

+0.3 pts

57th pct

Earnings growth

-1.9 pts

13th pct

Shareholder dilution

-2.1 pts

8th pct

Earnings quality

-3.5 pts

15th pct

Capital efficiency

-4.6 pts

4th pct

Profitability

-6.3 pts

8th pct

Free cash flow

-6.4 pts

8th pct

Scale

-6.4 pts

8th pct

Latest change (2026-08-06): 29 → 26 · ↓ Revenue growth 85→69

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CLPT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ClearPoint Neuro, Inc. (CLPT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLPT at 26.1/100 on a 32-signal composite quality model, placing it at rank #2,639 of 2,961 stocks — the bottom half of the AI-ranked universe. CLPT scores in the top quartile across revenue growth (84.0). Areas of concern include balance sheet strength (4.0) and free cash flow (7.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ClearPoint Neuro, Inc. reports quarterly revenue of $10.9M, net income of $-11.3M, an operating margin of -94.2%. Top institutional holders of CLPT by reported 13-F value include BlackRock, MAK CAPITAL ONE, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CLPT trades on the Nasdaq exchange and files with the SEC under CIK 1285550. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ClearPoint Neuro, Inc. directly from SEC EDGAR. ClearPoint Neuro, Inc.'s 13F Pro composite quality score has ranged between 25 and 30 since 2025, currently 26.1 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.

Revenue

Q2 2026

$10.9M

Net Income

Q2 2026

$-11.3M

Free Cash Flow

Q2 2026

$-7.2M

Operating Margin

Q2 2026

-94.2%

ROIC

Q2 2026

-67.2%

D/E Ratio

Q2 2026

4.66

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+17.8% YoY

$37.0MFY 2025

FY22 $20.6MFY23 $24.0MFY24 $31.4MFY25 $37.0M

Net Income

-35.0% YoY

$-25.5MFY 2025

FY22 $-16.4MFY23 $-22.1MFY24 $-18.9MFY25 $-25.5M

Operating Income

-22.4% YoY

$-24.2MFY 2025

FY22 $-16.3MFY23 $-22.4MFY24 $-19.7MFY25 $-24.2M

EPS (Diluted)

-28.6% YoY

$-0.90FY 2025

FY22 $-0.68FY23 $-0.90FY24 $-0.70FY25 $-0.90

Total Assets

+149.4% YoY

$97.7MFY 2025

FY22 $55.5MFY23 $42.7MFY24 $39.2MFY25 $97.7M

Total Debt

$49.1MFY 2025

FY22 $9.9MFY23 $9.9MFY24 —FY25 $49.1M

Op. Cash Flow

-167.3% YoY

$-23.9MFY 2025

FY22 $-16.2MFY23 $-13.7MFY24 $-8.9MFY25 $-23.9M

Free Cash Flow

-165.0% YoY

$-24.4MFY 2025

FY22 $-16.4MFY23 $-14.4MFY24 $-9.2MFY25 $-24.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$37.0M +17.8%	$31.4M +31.0%	$24.0M +16.6%	$20.6M +26.1%	$16.3M +27.0%	$12.8M
Net Income	$-25.5M -35.0%	$-18.9M +14.4%	$-22.1M -34.4%	$-16.4M -14.1%	$-14.4M -112.5%	$-6.8M
Operating Income	$-24.2M -22.4%	$-19.7M +12.1%	$-22.4M -37.4%	$-16.3M -22.1%	$-13.4M -115.0%	$-6.2M
EPS (Diluted)	$-0.90 -28.6%	$-0.70 +22.2%	$-0.90 -32.4%	$-0.68 +1.4%	$-0.69	—
Total Assets	$97.7M +149.4%	$39.2M -8.1%	$42.7M -23.1%	$55.5M -15.4%	$65.6M +122.2%	$29.5M
Total Debt	$49.1M	—	$9.9M +0.6%	$9.9M +0.6%	$9.8M -53.8%	$21.3M
Operating Cash Flow	$-23.9M -167.3%	$-8.9M +34.8%	$-13.7M +15.1%	$-16.2M -27.3%	$-12.7M -62.6%	$-7.8M
Free Cash Flow	$-24.4M -165.0%	$-9.2M +36.1%	$-14.4M +12.1%	$-16.4M -27.6%	$-12.9M -63.9%	$-7.8M

Get alerted when CLPT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ClearPoint Neuro, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CLPT

BlackRock, Inc.
$42.5M2,379,804 sh
MAK CAPITAL ONE LLC
$42.4M2,375,861 sh
VANGUARD CAPITAL MANAGEMENT LLC
$22.0M1,232,807 sh
STATE STREET CORP
$14.6M816,547 sh
GEODE CAPITAL MANAGEMENT, LLC
$13.4M749,932 sh
Lane Generational LLC
$7.9M444,831 sh
UBS Group AG
$7.6M428,632 sh
MILLENNIUM MANAGEMENT LLC
$6.4M357,676 sh
BROWN ADVISORY INC
$5.8M325,906 sh
COMPASS FINANCIAL MANAGEMENT LLC
$5.3M295,680 sh

Fund	Value	Shares
BlackRock, Inc.	$42.5M	2,379,804
MAK CAPITAL ONE LLC	$42.4M	2,375,861
VANGUARD CAPITAL MANAGEMENT LLC	$22.0M	1,232,807
STATE STREET CORP	$14.6M	816,547
GEODE CAPITAL MANAGEMENT, LLC	$13.4M	749,932
Lane Generational LLC	$7.9M	444,831
UBS Group AG	$7.6M	428,632
MILLENNIUM MANAGEMENT LLC	$6.4M	357,676
BROWN ADVISORY INC	$5.8M	325,906
COMPASS FINANCIAL MANAGEMENT LLC	$5.3M	295,680

Companies Similar to CLPT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

PRCT

PROCEPT BioRobotics Corp

AI score

Similar quality profile · 6 shared holders

Taylor Frigon Capital Management LLC FirstWave Capital Management LLC Lane Generational LLC

CBLL

Ceribell, Inc.

AI score

Similar quality profile · 4 shared holders

SILVERCREST ASSET MANAGEMENT GROUP LLC Numerai GP LLC Inscription Capital, LLC

RYTM

RHYTHM PHARMACEUTICALS, INC.

AI score

Similar quality profile · 5 shared holders

Longaeva Partners L.P.Exome Asset Management LLC SILVERCREST ASSET MANAGEMENT GROUP LLC

AUTL

Autolus Therapeutics plc

AI score

Similar quality profile · 1 shared holders

MAK CAPITAL ONE LLC

CARL

CARLSMED, INC.

AI score

Similar quality profile · 2 shared holders

Pier Capital, LLC Curated Wealth Partners LLC

TNGX

Tango Therapeutics, Inc.

AI score

Similar quality profile · 2 shared holders

Longaeva Partners L.P.Persistent Asset Partners Ltd

AGIO

AGIOS PHARMACEUTICALS, INC.

AI score

Similar quality profile · 3 shared holders

Exome Asset Management LLC Inscription Capital, LLC Hurley Capital, LLC

CVRX

CVRx, Inc.

AI score

Similar quality profile · 1 shared holders

SILVERCREST ASSET MANAGEMENT GROUP LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CLPT on your watchlist

Track score changes the day ClearPoint Neuro, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CLPT a good stock to buy?

13F Pro's AI-powered analysis of ClearPoint Neuro, Inc. (CLPT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLPT are available on the CLPT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CLPT is classified as a small company.

Which hedge funds own CLPT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLPT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ClearPoint Neuro, Inc.'s investment landscape.